Avania names first chief medical officer

Avania has appointed surgeon and former Edwards Lifesciences CMO Francis Duhay as its first chief medical officer, a new role aimed at deepening the CRO’s therapeutic expertise as MedTech development grows more complex. The hire is designed to strengthen support for sponsors from study design through commercialization across medical devices, diagnostics, and combination products.

Why it matters: - Avania is adding a top medical leadership role for the first time as it tries to sharpen its therapeutic expertise. - The move is meant to improve support for MedTech sponsors across clinical, regulatory, quality, medical affairs, and commercialization work. - As MedTech development becomes more complex, Avania is signaling that deeper disease-area knowledge is part of its growth strategy.

What happened: - Avania appointed Francis G. Duhay, MD, as chief medical officer on Aug. 20, 2026. - The company said the role is newly created. - Duhay will be based in the United States. - Duhay will lead the expansion of Avania’s internal therapeutic expertise and work with the company’s therapeutic franchise leaders. - Duhay will serve as a senior clinical resource to sponsors from study design through commercialization.

The details: - Duhay is a board-certified general and cardiothoracic surgeon. - He practiced surgery for more than a decade before moving into industry. - He started as an assistant professor of cardiothoracic surgery at Duke University Medical Center. - He later served as chief of cardiothoracic surgery at Kaiser Permanente. - In MedTech, Duhay held senior leadership roles at Edwards Lifesciences, where he also served as chief medical officer, and at Olympus Corporation. - He also led emerging diagnostics, biotechnology, and cardiovascular technology companies. - Duhay has led more than 90 clinical studies. - He has authored 45 peer-reviewed publications. - He holds 32 U.S. and international patents. - He has worked extensively with regulatory authorities worldwide. - Avania said the role will help align clinical, regulatory, quality, and medical affairs capabilities around a more integrated product-development and evidence-generation approach. - Jason Monteleone, president and CEO of Avania, said the new role reflects the company’s commitment to expanding therapeutic expertise and combining it with strategic, clinical, and operational insight. - William W. O'Neill, MD, said Duhay’s background across academic medicine and device innovation is an asset to Avania and its clients.

Between the lines: - The appointment suggests Avania is trying to differentiate itself in a crowded CRO market by adding high-level clinical expertise in-house. - Duhay’s mix of surgical, academic, and device-company experience fits Avania’s focus on complex MedTech programs that require both clinical judgment and regulatory fluency. - The emphasis on a single clinical perspective from first-in-human through commercialization points to a more integrated operating model.

What's next: - Duhay will help coordinate Avania’s development, regulatory, quality, clinical strategy, and medical affairs functions. - Avania is positioning the new role to support sponsors more consistently from early development through launch. - The company is likely to use the appointment to reinforce its pitch to both established MedTech firms and emerging innovators.

The bottom line: - Avania is betting that adding a first chief medical officer will strengthen its ability to guide MedTech products from concept to commercialization with deeper clinical leadership.